Subcutaneous · Glucagon receptor agonist
NNC9204-1513
1 trials in this molecule. Source: ClinicalTrials.gov, as of November 5, 2026.
Trials
1
Ongoing
0
Recruiting
0
Completed
1
Sites
1
Countries
1
Endpoints
27
Composite endpoints
0
Distinct sites and countries across this molecule's trials. A site running several of its trials counts once, matching the map.
Where the program stands
Trials by phase
Phase 1
1
Trials by status
Completed
1
Evidence coverage
What this asset has been measured on
Endpoints grouped into outcome categories, ranked by how often they are measured across this asset's trials.
Safety / tolerability / PK
11
Other (unclassified)
9
Glycemic / diabetes
3
Cardiometabolic biomarkers
3
Other clinical outcomes
1
Top 20 metrics across this asset's endpoints
Programs for this asset
Every trial for this molecule, with the same search, filters, and sort as the Trials tab.
⌘K
1 of 1
| Asset / Population | Eligibility highlight | Evidence | ||||||
|---|---|---|---|---|---|---|---|---|
| NCT03444467First Research Study to Compare a Possible New Medicine NNC9204-1513 to the Medicine Glucagon, in Healthy People. | NNC9204-1513 Type 1 diabetes, Type 2 diabetes | BMI 18.5-28 | Ph 1 | Completed | 1 | May 2018 | - |
Showing 1-1 of 1 trials